Dr. Martin is a Scientific Advisor in Oncology with TFS, Inc. since 2010 and Chief Medical Officer of the Melanoma Research Foundation Breakthrough Consortium
She has represented TFS in client meetings; provided input into clinical development plans, regulatory strategy and briefing documents; facilitated feasibility assessment and KOL relationships; served as a medical monitor; and, reviewed safety summaries for regulatory submission.
Dr. Martin received her medical degree from the George Washington University Medical School. She completed her residency & chief residency at the University Health Center Hospitals of Pittsburgh and fellowship training at the Clinical Oncology Program of the NCI.
A medical oncologist with 25+ years of multisector experience in clinical research, Dr. Martin helped design and oversee phase 1-3 trials sponsored by the U.S. National Cancer Institute (NCI) in academic institutions and the Cooperative Groups as a Senior Investigator in the Investigational Drug Branch and subsequently as Head of Melanoma and GU trials in the Cancer Treatment Evaluation Program (CTEP) of NCI. She has served on the DSMBs of multiple Cooperative Groups and on the NCI’s Central IRB (CIRB). Her regulatory experience includes 7 years as a reviewer and team leader in the oncology branch of the U.S. FDA. She has served on multiple subcommittees of ASCO, is a former board member of the Society for Melanoma Research, has served on the UK’s Clinical Trials Advisory and Awards Committee and the NCRN’s Peer Review Committee and EORTC’s Protocol Review Committee.